New IPF drug shows early promise in small safety trial

NCT ID NCT03422068

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested the safety and tolerability of a new drug called BI 1015550 (Nerandomilast) in 15 people with idiopathic pulmonary fibrosis (IPF). Participants took either the drug or a placebo twice daily for up to 12 weeks. The study aimed to see if the drug is safe and how the body processes it, laying groundwork for future larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 1015550 (Nerandomilast, JASCAYD®)
What this could lead to: If this drug proves safe and effective in larger trials, it could become a new treatment option for idiopathic pulmonary fibrosis.
What could go wrong: This is a very early Phase 1 trial with only 15 participants, so safety and effectiveness are not yet established. The drug may not work in larger studies or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Locations

Erasmus Medisch Centrum

Rotterdam, 3015 CE, Netherlands
Fraunhofer ITEM

Hanover, 30625, Germany
HYKS Keuhkosairauksien tutkimusyksikkö

Helsinki, 00290, Finland
Hospital de Bellvitge

L'Hospitalet de Llobregat, 08907, Spain
Odense University Hospital

Odense, 5000 C, Denmark
Poli Univ A. Gemelli

Roma, 00168, Italy
Royal Brompton Hospital

London, SW3 6NP, United Kingdom
Southampton General Hospital

Southampton, SO16 6YD, United Kingdom
St. Antonius ziekenhuis, locatie Nieuwegein

Nieuwegein, 3435 CM, Netherlands
TYKS

Turku, 20520, Finland
Universitätsklinikum Heidelberg

Heidelberg, 69126, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.